Pharmaceuticals News and Research

RSS

Positive results from Elevation Pharmaceuticals’ EP-101 Phase 2b study on COPD

Elevation Pharmaceuticals, Inc. today presented positive efficacy and safety results from the GOLDEN-1 study – a Phase 2b study evaluating EP-101 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) – at the annual meeting of the European Respiratory Society in Vienna, Austria.

3 Sep 2012

Dysfunctional RyRs play a role in stress-induced cognitive dysfunction

ARMGO Pharma, Inc., a biopharmaceutical company developing innovative small molecule drugs known as "Rycals™," which act on the ryanodine receptor calcium-release channel (RyR), announced that a study published today in the prestigious scientific journal Cell reveals the underlying role of calcium leak through the RyR as an important contributor to stress-induced cognitive dysfunction.

1 Sep 2012

Astellas Pharma adopts Advantest’s terahertz spectroscopic imaging system TAS7500

Advantest Corporation today announced that its terahertz spectroscopic imaging system TAS7500, which utilizes Advantest's THz wave technology, has been adopted by Astellas Pharma Inc.

31 Aug 2012

Addressing growing challenge of counterfeit drugs in developing world

"Many innovative solutions are being proposed to help tackle the spread of counterfeit drugs in developing countries," GlobalVoices reports. The blog includes highlights from several news articles and blog posts on the topic, including a number of solutions used to identify such drugs.

31 Aug 2012

Soligenix’s RiVax induces greater ricin neutralizing antibody levels in humans

Soligenix, Inc., a development stage biopharmaceutical company, announced today the results of a Phase 1B clinical trial of an aluminum hydroxide (Alum) adjuvanted formulation of RiVax, designed to improve the immunogenicity of the vaccine.

31 Aug 2012

FDA approves Ironwood’s LINZESS to treat irritable bowel syndrome with constipation

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. announced today that LINZESS (linaclotide) was approved by the U.S. Food and Drug Administration (FDA) as a once-daily treatment for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

31 Aug 2012

Bayer submits regorafenib NDA with FDA for treatment of metastatic and/or unresectable GIST

Bayer HealthCare and Onyx Pharmaceuticals today announced that Bayer HealthCare has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the oral multi-kinase inhibitor regorafenib for the treatment of metastatic and/or unresectable gastrointestinal stromal tumors (GIST) in patients whose disease has progressed despite prior treatment.

31 Aug 2012

Enrollment complete in Arrowhead’s CALAA-01 phase 1b trial on solid tumors

Arrowhead Research Corporation, a targeted therapeutics company, today announced that, through its Calando Pharmaceuticals subsidiary, it has completed enrollment of a phase 1b clinical trial of CALAA-01, its RNAi therapeutic candidate targeting solid tumors. All patients participating in the trial have completed dosing with the exception of one patient who is still receiving treatment and will continue to be monitored.

31 Aug 2012

Ironwood receives FDA approval for Linzess to treat chronic idiopathic constipation, IBS

The U.S. Food and Drug Administration today approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation (IBS-C) in adults.

31 Aug 2012

Chronic nerve pain: an interview with Professor Sally Lawson

Chronic nerve pain results from pathological changes within a nerve that appear to be self-sustaining and thus the pain continues for a long time.

30 Aug 2012

Bradykinesia in Parkinson’s disease: an interview with Dr. Joseph Giuffrida, President of Great Lakes NeuroTechnologies

Currently in the United States, there are over 1.5 million people living with Parkinson's and 50,000 new cases reported each year

30 Aug 2012

IQWiG examines added benefit of belimumab for patients with systemic lupus erythematosus

Belimumab has been approved since July 2011 as an add-on therapy for adult patients with the autoimmune disease systemic lupus erythematosus (SLE). Products (AMNOG).

30 Aug 2012

Combination of POZEN’s PA32540 and clopidogrel results in greater antiplatelet effects

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced the presentation of Phase 1 data, at the European Society of Cardiologists 2012 Congress, from a study of PA32540, a novel coordinated-delivery tablet of enteric-coated (EC) aspirin (325 mg) and immediate-release (IR) omeprazole (40 mg).

30 Aug 2012

Protalex announces results from PRTX-100 Phase 1b trial on active rheumatoid arthritis

Protalex, Inc., a clinical stage biopharmaceutical company focused on the development of a class of drugs designed to treat autoimmune and inflammatory diseases including rheumatoid arthritis (RA), today announced results from its recently completed Phase 1b randomized, multiple-dose, dose-escalation study.

30 Aug 2012

Collegium commences enrollment in Oxycodone DETERx Phase 3 study in chronic lower back pain

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain today announced that it has initiated enrollment in its Phase 3 clinical study for Oxycodone DETERx (COL-003).

30 Aug 2012

Genmab, Janssen partner to develop and commercialize daratumumab for multiple myeloma

Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has executed a global license and development agreement with the Danish company Genmab A/S for the anti-cancer compound, daratumumab.

30 Aug 2012

PrecisionMed announces enrollment of first donor into Amyotrophic Lateral Sclerosis Registry

PrecisionMed Inc., the world's leading supplier of human cerebrospinal fluid (CSF), today announced enrollment of the first donor into the PrecisionMed Amyotrophic Lateral Sclerosis (ALS) Registry.

30 Aug 2012

Noven submits LDMP NDA with FDA to treat menopausal vasomotor symptoms

Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that it has submitted to the U.S. Food & Drug Administration a New Drug Application (NDA) seeking approval to market low-dose mesylate salt of paroxetine (LDMP) for the treatment of vasomotor symptoms associated with menopause.

30 Aug 2012

FDA grants orphan designation to Aerial BioPharma’s ARL-N05 for treatment of narcolepsy

Aerial BioPharma, a biopharmaceutical company focused on developing biologics and small molecules for conditions in the central nervous system, has received orphan drug designation for its narcolepsy drug in development.

30 Aug 2012

Charles River announces acquisition of Accugenix

Charles River Laboratories International, Inc. announced today that it has acquired Accugenix, Inc., the premier global provider of cGMP-compliant contract microbial identification testing, for approximately $17 million in cash.

30 Aug 2012

Pharmaceuticals News and Research

Positive results from Elevation Pharmaceuticals’ EP-101 Phase 2b study on COPD

Dysfunctional RyRs play a role in stress-induced cognitive dysfunction

Astellas Pharma adopts Advantest’s terahertz spectroscopic imaging system TAS7500

Addressing growing challenge of counterfeit drugs in developing world

Soligenix’s RiVax induces greater ricin neutralizing antibody levels in humans

FDA approves Ironwood’s LINZESS to treat irritable bowel syndrome with constipation

Bayer submits regorafenib NDA with FDA for treatment of metastatic and/or unresectable GIST

Enrollment complete in Arrowhead’s CALAA-01 phase 1b trial on solid tumors

Ironwood receives FDA approval for Linzess to treat chronic idiopathic constipation, IBS

Chronic nerve pain: an interview with Professor Sally Lawson

Bradykinesia in Parkinson’s disease: an interview with Dr. Joseph Giuffrida, President of Great Lakes NeuroTechnologies

IQWiG examines added benefit of belimumab for patients with systemic lupus erythematosus

Combination of POZEN’s PA32540 and clopidogrel results in greater antiplatelet effects

Protalex announces results from PRTX-100 Phase 1b trial on active rheumatoid arthritis

Collegium commences enrollment in Oxycodone DETERx Phase 3 study in chronic lower back pain

Genmab, Janssen partner to develop and commercialize daratumumab for multiple myeloma

PrecisionMed announces enrollment of first donor into Amyotrophic Lateral Sclerosis Registry

Noven submits LDMP NDA with FDA to treat menopausal vasomotor symptoms

FDA grants orphan designation to Aerial BioPharma’s ARL-N05 for treatment of narcolepsy

Charles River announces acquisition of Accugenix

Event guide: World ADC London eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence